MENINGOCOCCAL

(MCV4-MENACTRA) VACCINE

VACCINE USAGE: Menactra is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent N meningitidis serogroup B disease.

VACCINE DOSAGE: a 0.5 mL dose for intramuscular injection.

PRIMARY VACCINATION:

  • Children 9 through 23 months of age: Two doses, three months apart.
  • Individuals 2 through 55 years of age: A single dose.

BOOSTER VACCINATION:

  • A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose.

VACCINE INGEDIENTS: formaldehyde, phosphate buffers, Mueller Hinton agar, Watson Scherp media, modified Mueller and Miller medium.

ADVERSE VACCINE REACTIONS: diarrhea, drowsiness, anorexia, arthralgia, fever, rash, vomiting, seizure, headache, chills, hypersensitivity reactions such as anaphylaxis/ anaphylactic reaction, wheezing, difficulty breathing, upper airway swelling, urticaria, erythema, pruritus, hypotension, Guillain- Barre syndrome, paraesthesia, vasovagal syncope, dizziness, convulsion, facial palsy, acute disseminated encephalomyelitis, transverse myelitis, myalgia.